Get the Stockscreener App
0.6895
0.87%
0.00594
After Hours:
.68
-0.0095
-1.38%
InspireMD Inc. stock is traded at $0.6895, with a volume of 27,718.
It is up +0.87% in the last 24 hours and down -4.24% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$0.6836
Open:
$0.68
24h Volume:
27,718
Relative Volume:
0.10
Market Cap:
$32.30M
Revenue:
$10.85M
Net Income/Loss:
$-51.31M
P/E Ratio:
-0.9355
EPS:
-0.737
Net Cash Flow:
$-40.15M
1W Performance:
-2.05%
1M Performance:
-4.24%
6M Performance:
-58.21%
1Y Performance:
-71.63%
1-Day Range:
$0.661
$0.7163
1-Week Range:
$0.661
$0.72
52-Week Range:
$0.63
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.6895 | 32.02M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Maxim Group | Buy |
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
NSPR|InspireMD Inc|Price:0.694|Chg%:+0.010 - TradingKey
InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InspireMD Inc (NSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InspireMD Inc. Revenue Breakdown – NASDAQ:NSPR - TradingView
InspireMD Inc. (NSPR) Q1 2026 Earnings: EPS Surpasses Estimates Despite Limited Revenue DisclosureGuidance Downgrade Alert - dars.gov.et
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InspireMD, Inc. Receives Notice of Delisting from NASDAQ – Form 8-K Filing July 2026 - Minichart
InspireMD Receives Nasdaq Minimum Bid Price Warning - Moomoo
InspireMD Inc (NSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InspireMD Receives Nasdaq Notice on Bid Price Compliance - TipRanks
InspireMD Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
InspireMD (NSPR) warned by Nasdaq over $1.00 bid price and delisting risk - Stock Titan
InspireMD gets Nasdaq notice for failing $1 minimum bid price rule - Bitget
InspireMD director Raymond W. Cohen to resign from board effective July 1, 2026 - TradingView
Board member Raymond Cohen to leave InspireMD (NSPR) effective July 1, 2026 - Stock Titan
InspireMD (NSPR) Slips 4.5% on Selling Pressure, Tests Key Support LevelPut Spread Alert - dars.gov.et
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
InspireMD, Inc.(NasdaqCM: NSPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBITDA forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to revenue forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBIT forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Price to earnings forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
InspireMD Inc. Actuals & Estimates (NASDAQ:NSPR) - TradingView
NSPR Forecast — Price Target — Prediction for 2027 - TradingView
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc (NSPR) Institutional Confidence - TradingKey
InspireMD, Inc. Announces Recalling of Cguard Prime Carotid Stent System 135Cm, 8Mmx30mm - marketscreener.com
NSPR Q1 2026 Earnings: EPS Beat Surprises as Revenue Remains UndisclosedEPS Consistency Score - dars.gov.et
InspireMD Inc (NSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InspireMD Inc (NSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InspireMD Inc (NSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InspireMD Inc. (NSPR) Gains Momentum: Breaking Above Key SupportMarket Leader Picks - dars.gov.et
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR - Yahoo Finance
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
InspireMD (NSPR) Edges Higher but Faces Test at $0.77 ResistanceRating Change - dars.gov.et
InspireMD Inc. (NSPR) Holds at $0.73 After Fractional Gain, Testing Key Support ZoneStock Buy Zone - newsline.com
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementProfit Margin Analysis - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Inspire announces 30-day CGUARDIANS II results; 100% acute device success, no 30-day MACEs - TradingView
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
InspireMD reports 30-day success in trial for C... - Pluang
NSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):